Skip to main content

View Resource

Published

Efficacy and safety of rivaroxaban, colchicine, and famotidine–loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial.
STIMULATE-ICP consortium. The Lancet Infectious Diseases 2026;:https://doi.org/10.1016/S1473-3099(26)00242-2.
[In participants with long COVID, severe fatigue reduced in all study groups—including the no drug group—over 12 weeks, with small additional reductions in the colchicine and famotidine–loratadine groups compared with the no drug group. Modest effects on FAS were not sustained after drug withdrawal. Future trials could investigate the use of these or other repurposed drugs in specific subgroups of patients with long COVID, combination therapies, and how care is delivered.]
Freely available online
Age Groups
Adults
Conditions and Lifestyle Factors
Coronavirus Infections
Settings
Community Clinics
General Practice
Staff Groups
Drug Therapy
Medic